stoxline Quote Chart Rank Option Currency Glossary
Legend Biotech Corporation (LEGN)
41.255  -0.245 (-0.59%)    06-18 11:13
Open: 41.58
High: 41.58
Volume: 106,732
Pre. Close: 41.5
Low: 40.54
Market Cap: 7,520(M)
Technical analysis
2024-06-18 10:50:49 AM
Short term     
Mid term     
Targets 6-month :  51.1 1-year :  54.82
Resists First :  43.75 Second :  46.93
Pivot price 43.12
Supports First :  38.59 Second :  32.11
MAs MA(5) :  42.89 MA(20) :  42.74
MA(100) :  52.86 MA(250) :  60.61
MACD MACD :  -0.8 Signal :  -0.9
%K %D K(14,3) :  36.9 D(3) :  49.4
RSI RSI(14): 41.1
52-week High :  77.31 Low :  38.59
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LEGN ] has closed above bottom band by 25.4%. Bollinger Bands are 12.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 43.64 - 43.99 43.99 - 44.23
Low: 40.39 - 40.77 40.77 - 41.02
Close: 41 - 41.59 41.59 - 41.99
Company Description

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Headline News

Tue, 18 Jun 2024
Legend Biotech (NASDAQ:LEGN) Given Overweight Rating at Piper Sandler - Defense World

Mon, 17 Jun 2024
Legend Biotech (NASDAQ:LEGN) Shares Gap Up to $42.45 - MarketBeat

Mon, 17 Jun 2024
Legend Biotech (NASDAQ:LEGN) Receives "Overweight" Rating from Piper Sandler - MarketBeat

Mon, 17 Jun 2024
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst - Legend Biotech (NASDAQ:LEGN) - Benzinga

Mon, 17 Jun 2024
Quarry LP Buys New Position in Legend Biotech Co. (NASDAQ:LEGN) - Defense World

Wed, 29 May 2024
Legend Biotech to Participate in the Jefferies Global Healthcare Conference - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 182 (M)
Shares Float 160 (M)
Held by Insiders 1.3 (%)
Held by Institutions 49 (%)
Shares Short 12,980 (K)
Shares Short P.Month 10,980 (K)
Stock Financials
EPS -2.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.38
Profit Margin -136 %
Operating Margin -125.5 %
Return on Assets (ttm) -18.3 %
Return on Equity (ttm) -51.3 %
Qtrly Rev. Growth 158.6 %
Gross Profit (p.s.) 0
Sales Per Share 1.88
EBITDA (p.s.) -2.34
Qtrly Earnings Growth 0 %
Operating Cash Flow -239 (M)
Levered Free Cash Flow -264 (M)
Stock Valuations
PE Ratio -15.94
PEG Ratio 0
Price to Book value 6.43
Price to Sales 21.85
Price to Cash Flow -31.41
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android